Haemophilia

·MeSH: Hemophilia A

Prevalence

5.0 / 100K

10 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(6)

Phase 2(1)

Drug	Company
nnc0442-0344 a	Novo Nordisk A/S (NVO)

Unknown(2)

Drug	Company
esperoct	Novo Nordisk A/S (NVO)
refixia	Novo Nordisk A/S (NVO)

Phase 1/Phase 2(1)

Drug	Company
valoctocogene roxaparvovec	BIOMARIN PHARMACEUTICAL INC (BMRN)

BioSniper tracks 10 drugs in development for Haemophilia across 2 companies.

There are 1 clinical trial targeting Haemophilia tracked by BioSniper.

The estimated prevalence of Haemophilia is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.